Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07174388 · ClinicalTrials.gov registry record
A Study in Non-Small Cell Lung Cancer
A clinical trial of Non-Small Cell Lung Cancer, sponsored by N-Power Medicine.
- Recruiting
- Registry status
- 550
- Enrollment target
- 3
- Study locations
NCT07174388 is a study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by N-Power Medicine. The registered enrollment target is 550 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (16% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT07174388, a study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by N-Power Medicine.
- RECRUITING
- Registry status
- 550 participants
- Enrollment target
- 3
- Study locations
Study Summary
A study to create control arms using current and future information in patients with lung cancer that has spread who have already received chemotherapy.
Conditions Studied
Study Locations (3)
Delaware
- Bayhealth Medical Center, Kent Campus - Dover
- Bayhealth Medical Center- Sussex Campus - Milford
California
- Pacific Cancer Care - Monterey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 550 participants |
| Start Date | 2026-01-07 |
| Est. Completion | 2029-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07174388
The ClinicalTrials.gov registry entry for NCT07174388 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 550 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (16% lower). The listed sponsor is N-Power Medicine, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT07174388 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Delaware, California.
Frequently Asked Questions
What is clinical trial NCT07174388 about?
NCT07174388 is a clinical study titled "A Study in Non-Small Cell Lung Cancer". A study to create control arms using current and future information in patients with lung cancer that has spread who have already received chemotherapy.
What is the current status of trial NCT07174388?
This trial is currently recruiting. The enrollment target is 550 participants. The study started on 2026-01-07. Estimated completion is 2029-04.
What conditions does trial NCT07174388 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
Who is sponsoring clinical trial NCT07174388?
This trial is sponsored by N-Power Medicine, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07174388 being conducted?
This trial has 3 study locations across California, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.